Results for
""Bezafibrate""[mesh_terms]

Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women.

S Higashio, T Ushiroyama, A Ikeda, M Ueki

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2001;11(8):709-14

Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.

Mana Nishida, Takeshi Horio, Yusuke Fukuda, Yuki Hayakawa, Yu Tateishi, Mayumi Akai, Masanori Emoto, Takamasa Hasegawa, Masahito Imanishi

International journal of clinical pharmacology and therapeutics 2023;61(10):437-444

Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.

Kou Sakuma, Sakura Nosaka, Takahisa Ushiroyama

Journal of cardiovascular pharmacology and therapeutics 2006;11(2):142-8

The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis.

G Grammatikos, H Farnik, D Bon, A Böhlig, T Bader, T Berg, S Zeuzem, E Herrmann

Journal of viral hepatitis 2015;21(8):533-41

The role of fibric acid derivatives in the secondary prevention of coronary heart disease.

J Krakoff, B S Vela, E A Brinton

Current cardiology reports 2000;2(5):452-8

Role of fibrates in reducing coronary risk: a UK Consensus.

Current medical research and opinion 2004;20(2):241-7

Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).

Valentina Boyko, Solomon Behar, Ilan Goldenberg, Uri Goldbourt, Henrietta Reicher-Reiss

The American journal of cardiology 2006;97(4):466-71

Update on the use of fibrates: focus on bezafibrate.

Ilan Goldenberg, Michal Benderly, Uri Goldbourt

Vascular health and risk management 2008;4(1):131-41

Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study.

Tomomitsu Ohshima, Kimiko Terasawa, Yuuko Uchida, Hidefumi Ohsawa, Yasumi Uchida, Yoshiharu Fujimori, Junichi Hirose, Hirofumi Noike, Kohei Kawamura, Katsumi Yamada, Hiroshi Morio, Masaaki Ozegawa, Michihisa Kaku, Kunio Yoshinaga, Shin Sato, Takeshi Sakurai, Kaneyuki Aoyagi, Takashi Hitsumoto, Hiroshi Sakuragawa, Masahito Kanai, Keiichi Tokuhiro

Japanese heart journal 2002;43(4):319-31

Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects.

Jennifer Tremblay-Mercier, Daniel Tessier, Mélanie Plourde, Mélanie Fortier, Dominique Lorrain, Stephen C Cunnane

The Journal of pharmacology and experimental therapeutics 2010;334(1):341-6

Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.

Ilan Goldenberg, Valentina Boyko, Alexander Tennenbaum, David Tanne, Solomon Behar, Victor Guetta

Archives of internal medicine 2009;169(5):508-14

Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.

Zaza Iakobishvili, Tal Hasin, Robert Klempfner, Nir Shlomo, Ilan Goldenberg, Ronen Brenner, Ran Kornowski, Yariv Gerber

Mayo Clinic proceedings 2020;94(7):1171-1179

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

F Chiodo, R Manfredi

The Journal of infection 2001;42(3):181-8

Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia.

Teruyoshi Kihara, Makoto Ayaori, Yukihiko Momiyama, Zahi A Fayad, Atsushi Yonemura, Reiko Ohmori, Kazuhiro Nakaya, Nobukiyo Tanaka, Masatsune Ogura, Shojiro Sawada, Hiroaki Taniguchi, Masatoshi Kusuhara, Masayoshi Nagata, Haruo Nakamura, Fumitaka Ohsuzu

Atherosclerosis 2008;196(1):425-433

Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.

D P Mikhailidis, E Rizos

International journal of cardiology 2002;82(3):199-207; discussion 207-8